Motif Bio appoints former investment banker as CFO
AIM and Nasdaq-listed antibiotics developer Motif Bio appointed pharmaceutical veteran and former investment banker Robert Dickey as chief financial officer.
MOTIF BIO
£0.01
08:30 29/07/20
He will succeed Peter Meyers, who will transition his responsibilities to Dickey over the next several weeks.
Dickey was previously chief financial officer at Nasdaq-listed oncology firm Tyme Technologies, and has worked at Caladrius Biosciences, Hemispherx Biopharma, Stemcyte, Locus Pharmaceuticals and Protarga.
He began his career as an investment banker at the now defunct Lehman Brothers and Legg Mason Wood Walker.
Chief executive Graham Lumsden, said: "Rob's proven leadership and strategic skills will be a tremendous addition to the team. I am immensely grateful to Pete Meyers for his tireless dedication and hard work during 2016, culminating in a successful Nasdaq initial public offering and raise of $25m. I wish him well in his future endeavours."
Motif Bio is currently awaiting data in the second quarter of 2017 from Revive-1, its phase three clinical trial in patients with acute bacterial skin and skin structure infections.
Shares in Motif Bio were down 1.96% to 25p at 1207 GMT.